Conatus Pharmaceutic (CNAT) Stock Price, Quote, News and Overview
NASDAQ:CNAT - Nasdaq -
CNAT Quote, Performance and Key Statistics
0.556
+0 (+0.18%)
The current stock price of CNAT is 0.556 null. In the past month the price increased by 61.16%. In the past year, price decreased by -28.02%.
About CNAT
Company Profile
Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California.
Company Info
Conatus Pharmaceutic
16745 W. Bernardo Dr. Suite 250
San Diego CA 92127
CEO: Steven J. Mento
Phone: 858-376-2600
Conatus Pharmaceutic / CNAT FAQ
What is the stock price of Conatus Pharmaceutic today?
The current stock price of CNAT is 0.556 null. The price increased by 0.18% in the last trading session.
What is the ticker symbol for Conatus Pharmaceutic stock?
The exchange symbol of Conatus Pharmaceutic is CNAT and it is listed on the Nasdaq exchange.
On which exchange is CNAT stock listed?
CNAT stock is listed on the Nasdaq exchange.
What is Conatus Pharmaceutic worth?
Conatus Pharmaceutic (CNAT) has a market capitalization of 18.44M null. This makes CNAT a Nano Cap stock.
What are the support and resistance levels for Conatus Pharmaceutic (CNAT) stock?
Conatus Pharmaceutic (CNAT) has a support level at 0.55 and a resistance level at 0.61. Check the full technical report for a detailed analysis of CNAT support and resistance levels.
Should I buy Conatus Pharmaceutic (CNAT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CNAT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CNAT, evaluating the profitability, health, valuation and growth aspects
- Conatus Pharmaceutic (CNAT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Conatus Pharmaceutic (CNAT) Sales and EPS estimates to see what analysts future expectations are.
- Conatus Pharmaceutic (CNAT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Conatus Pharmaceutic (CNAT) Insider and Institutional Ownership to learn about the owners and their transactions.
- Conatus Pharmaceutic (CNAT) Stock Chart to make your own analysis
- Conatus Pharmaceutic (CNAT) Latest news and press-releases to stay up to date.
Does Conatus Pharmaceutic (CNAT) stock pay dividends?
CNAT does not pay a dividend.
What is the Price/Earnings (PE) ratio of Conatus Pharmaceutic (CNAT)?
Conatus Pharmaceutic (CNAT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.34).
CNAT Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CNAT. When comparing the yearly performance of all stocks, CNAT is one of the better performing stocks in the market, outperforming 72.81% of all stocks.
CNAT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CNAT. While CNAT seems to be doing ok healthwise, there are quite some concerns on its profitability.
CNAT Financial Highlights
Over the last trailing twelve months CNAT reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS increased by 42.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -68.87% | ||
| ROA | -53.86% | ||
| ROE | N/A | ||
| Debt/Equity | 0.01 |